Industry News-Good Doctor

Blog

——

Corporate News

Industry News

Hyperthermic Perfusion Podcast

Notice & Announcement

2026.03.03

[Exhibition News] 2026 China Integrated Oncology Conference – November 12–15, Changsha, Hunan Province

The Xiang River flows majestically, and Mount Lu rises grandly—standing at the forefront of integrative medicine; the ancient lands of Xiaoxiang and Shusi, steeped in sacred history, are painting a grand vision for global cancer combat. Embracing the spiritual essence of mountains and waters, we usher in a grand gathering for our times. From November 12 to 15, 2026, the highly anticipated 2026 China Conference on Integrative Oncology (CCHI0) will be held with great splendor in Changsha, the “City of Stars.” This conference is organized by the Chinese Anti-Cancer Association (CACA), co-organized by the International Association for Holistic and Integrative Medicine (IAHIM), the World Association for Integrative Oncology (WAIO), and the Hunan Provincial Anti-Cancer Association, and hosted by the Hunan Provincial Tumor Hospital.

2026.02.28

Reprinted: Expert Consensus on the Comprehensive Diagnosis and Treatment of Peritoneal Metastasis from Appendiceal Epithelial Tumors (2025 Edition)

Appendiceal epithelial tumors refer to neoplastic lesions originating from the mucosal epithelium of the appendix. These tumors exhibit marked heterogeneity in their pathological features and biological behavior. Due to their unique structural and biological characteristics, they have a high propensity for peritoneal metastasis. Currently, there is limited evidence-based medical support for the diagnosis and treatment of appendiceal epithelial tumors and their peritoneal metastases, and clinical practice still lacks unified guidelines. To address this gap, the Specialist Committee on Integrated Rehabilitation for Peritoneal Tumors of the Chinese Anti-Cancer Association has brought together multidisciplinary experts to systematically integrate specialized technical expertise around key aspects including pathological classification and clinical staging of appendiceal epithelial tumors, indications for extended resection following local excision, surgical strategies for managing concurrent peritoneal metastases, perioperative rehabilitation, and personalized treatment approaches. At the same time, the committee has standardized the perioperative management of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC), as well as the clinical application of prehabilitation protocols, thereby enhancing the practicality and operability of these procedures. Ultimately, the "Expert Consensus on Comprehensive Diagnosis and Treatment of Peritoneal Metastasis from Appendiceal Epithelial Tumors (2025 Edition)" has been developed. This consensus aims to further standardize the systematic diagnostic and therapeutic workflows for appendiceal epithelial tumors, reduce the risk of recurrence, improve patient outcomes, and promote the standardization and homogenization of the diagnosis and treatment of peritoneal metastases from these tumors.

2026.01.22

[Exhibition News] The 29th Annual Academic Conference of the Chinese Society of Clinical Oncology (CSCO), 2026

This conference will continue to uphold the fundamental mission of CSCO, further promoting academic exchanges and scientific-technological cooperation in the fields of clinical oncology both internationally and domestically. It will encourage and support clinical research and innovation, advocate precision oncology based on multidisciplinary, standardized, and comprehensive treatment approaches, and actively advance the development of the discipline.

2025.12.19

Reprinted from: [Literature Interpretation] Pharmacokinetic Study of Paclitaxel Combined with Cisplatin Intraperitoneal Hyperthermic Perfusion Chemotherapy

Intraperitoneal combined hyperthermic chemotherapy with CDDP and PTX results in drug concentrations within the peritoneal cavity that far exceed plasma drug levels. This pharmacokinetic profile enables the maximum antitumor effect on micrometastatic foci in the peritoneal cavity while minimizing systemic toxicity. HIPEC can effectively reduce the risk of recurrence caused by micrometastatic disease, and elevated temperatures enhance the efficacy of chemotherapeutic agents. Post-CRS, intracavitary hyperthermic perfusion chemotherapy with CDDP and PTX is both safe and feasible, offering significant pharmacokinetic advantages.

2025.12.13

Reprinted from: [Interpretation] Perioperative Hyperthermic Intraperitoneal Chemotherapy for Stage T4 Colorectal Cancer: Can It Improve Patient Prognosis? Propensity Score Matching

In this study, prophylactic HIPEC reduced the risk of PM in patients with cT4N0-1M0 disease and significantly improved DFS. Postoperative prophylactic HIPEC did not significantly increase the incidence of surgery-related complications. Meanwhile, performing HIPEC after laparoscopic surgery in T4-stage CRC patients is relatively safe and does not increase the risk of peritoneal implantation or metastasis. Prophylactic hyperthermic intraperitoneal chemotherapy for T4-stage colorectal cancer has been shown to be effective [strong] and is worthy of clinical adoption!

2025.07.09

How to trace the origin of peritoneal metastasis? A review of treatment strategies

For a long time, it was believed that once tumors metastasized to the peritoneum, they were in the late stage, with limited treatment options and poor prognosis. With the updating of treatment concepts and the establishment of treatment strategies centered on cytoreductive surgery (CRS) + hyperthermic intraperitoneal chemotherapy (HIPEC), patients' prognosis and quality of life have been greatly improved, and some patients may even achieve clinical cure.

2025.04.29

Good Doctor. Hyperthermic Intraperitoneal Chemotherapy (HIPEC)丨Reprint 5: Focus on active treatment options for peritoneal surface malignancies. Research progress on cytoreductive surgery and HIPEC in Northern Europe.

Colorectal cancer with peritoneal metastasis remains a significant therapeutic challenge. While cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (HIPEC) has been the mainstay of treatment, questions regarding the optimal HIPEC regimen persist. The PRODIGE7 trial challenged the efficacy of oxaliplatin-based HIPEC, leading to a greater focus on novel combination therapies. The ongoing EFFIPEC trial aims to refine HIPEC regimens by evaluating intensified chemotherapy regimens. This article provides an update on the interim analysis of this trial and highlights international collaborations, particularly with the HIPEC network of the Indian Society of Peritoneal Surface Malignancies (INDEPSO). Furthermore, potential new research initiatives in the Nordic countries regarding pseudomyxoma peritonei are introduced.

2025.04.29

Good Doctor. Hyperthermic Intraperitoneal Chemotherapy (HIPEC): Alternative to Traditional HIPEC - Three and Four Cycles of HIPEC

Intraperitoneal hyperthermic chemotherapy (IPHC) has remained largely unchanged in the past 30 years. It is used to prevent peritoneal metastasis in patients with a high risk of disease progression in gastric or colorectal cancer, and more commonly to treat patients with peritoneal metastasis from ovarian, gastric, colorectal, and appendiceal cancers. After undergoing cytoreductive surgery, IPHC is used to help maintain a disease-free state in the peritoneal and pelvic cavities. From a theoretical perspective and analysis of IPHC failures, this treatment method has several shortcomings. First, perhaps the most serious criticism of IPHC is its insufficient "dwell time" in the peritoneal and pelvic cavities. The chemotherapy solution is maintained at 41-43 degrees Celsius using a hyperthermia pump for only 90 minutes. This limited drug exposure time is even more problematic for residual micrometastases, as high intraperitoneal concentrations of most chemotherapeutic drugs are only maintained for 30-60 minutes. High-molecular-weight drugs like paclitaxel diffuse more slowly from the peritoneal cavity. Low-molecular-weight drugs like cisplatin no longer maintain high concentrations in the peritoneal cavity after only 20 minutes. My conclusion is that increasing the dwell time of chemotherapeutic drugs in the peritoneal cavity is the primary condition for achieving greater efficacy of IPHC.

< 1 2 3 4 5 > proceed page

· GDHIPEC from China ,

· Caring for Patients Worldwide ·

Tel.: +86 29 82681864

Sales service hotline: +86 15002902555

E-mail: gd029@126.com

Address: Floor 1-2, Left Building No. 1, Huoju Road, East zone of Xi’an High- tech Development District, Xi’an, China

COOKIES

Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy

COOKIES

required

These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.

analyze

These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.

Feature

These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.

advertise

These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.

Internet Drug Information Service Qualification Certificate (Shaanxi)-Non-Operating -2023-0143

Blog

COOKIES

COOKIES

Sorry，The current column has no content!